NovaBay Pharmaceuticals Strengthens Global Aganocide(R) Patent Estate With Seven New Patents
31 mai 2012 18h07 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 31, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage biotechnology company developing first-in-class "non-antibiotic anti-infective"...
NovaBay Enrolls First Patients in Global BAYnovation(TM) Phase 2b Study for Adenoviral Conjunctivitis
17 mai 2012 07h00 HE
|
NovaBay Pharmaceuticals, Inc.
Study Design Includes FDA Recommendations Following Successful End-of-Phase 2a Meeting
EMERYVILLE, Calif., May 17, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY),...
NovaBay Pharmaceuticals Provides Q1 - 2012 Financial Results
03 mai 2012 08h05 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing novel anti-infective products for the treatment and...
NovaBay's Aganocide Out-Performed Traditional Antibiotics in Drug Resistance Study
02 mai 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
Findings Published in Antimicrobial Agents and Chemotherapy Show Resistance to NVC-422 Does Not Emerge in S. aureus Including MRSA, P. aeruginosa, and E. coli Bacteria
EMERYVILLE, Calif., May 2,...
NovaBay's NeutroPhase(R) Supports Healing of Chronic Wounds
19 avr. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
New Patient Case Studies Highlighted at the 2012 Spring Symposium on Advanced Wound Care
EMERYVILLE, Calif., April 19, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE AMEX:NBY),...
NovaBay to Present New Case Studies on NeutroPhase(R) at the 2012 Spring Symposium on Advanced Wound Care
16 avr. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 16, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE AMEX:NBY), a biotech company developing novel anti-infective products for the treatment and prevention...
NovaBay Pharmaceuticals Launches CEO Blog
05 avr. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
Follow NovaBay on Twitter, Facebook and Linkedin
EMERYVILLE, Calif., April 5, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company...
NovaBay Pharmaceuticals Provides Fourth Quarter and Full Year 2011 Financial Results
27 mars 2012 07h45 HE
|
NovaBay Pharmaceuticals, Inc.
Progress Continues in Company's Four Business Units:
Ophthalmology: Enrollment in global adenoviral conjunctivitis study to begin Q2-2012.
Urology: Demonstrated 80% effectiveness...
NovaBay Pharmaceuticals Signs Option Agreement With Virbac Animal Health for Aganocide(R) Compounds
20 mars 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company today announced that it has entered into a feasibility...
NovaBay Pharmaceuticals to Present at Two Upcoming Investor Conferences in March
06 mars 2012 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 6, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...